Asia-Pacific Navigates the Aging Indication Gap Through Three Distinct Routes, but Therapeutic Development Lags Behind Service Delivery
核心洞察
No regulatory jurisdiction worldwide recognizes aging as an approvable indication, forcing Asia-Pacific stakeholders to pursue three alternative routes: service provision, borrowed indications, and biomarker qualification.
Japan's Act on the Safety of Regenerative Medicine has enabled over 1,000 approved provision plans and more than 10,000 patients treated annually, creating the world's largest lawful market for unapproved cell-based therapy.
The Asian Working Group for Sarcopenia (搜索) has established Asia-calibrated diagnostic criteria and published a 2025 consensus update in Nature Aging, yet holds only four of 22 seats on the Global Leadership Initiative in Sarcopenia steering committee.
No regulatory jurisdiction on earth recognizes aging as an approvable indication. The position is clearest in the United States, where the FDA's non-recognition of aging as an indication has been the field's defining constraint for a decade, and as of mid-2026, no epigenetic clock has been accepted as a surrogate endpoint. Nothing in the published positions of Japan's PMDA, China's NMPA, Korea's MFDS, Singapore's HSA, India's CDSCO or Australia's TGA departs from that. A sponsor cannot file for aging. It can only file for something aging causes.
Against this regulatory reality sits an urgent demographic picture. Japan, South Korea, Taiwan and Singapore have already crossed into super-aged classification, Thailand and Malaysia are close behind, and by 2030 one in four people in Asia will be over 60. There is no other region where the gap between demand for an intervention and the legal availability of one is this wide, this rich, or this politically urgent.
When demand of that size meets a closed front door, the traffic does not stop. It goes around. In Asia-Pacific it has gone around by three distinct routes, and the difference between them is not scientific sophistication but where the evidence obligation sits.
Route One: Selling Longevity as a Medical Service
Japan built the door more than a decade ago. The Act on the Safety of Regenerative Medicine, promulgated in 2013 and implemented on 25 November 2014, regulates the provision of regenerative medicine using cell products that have not been approved under the Pharmaceuticals and Medical Devices Act, allowing them to be provided either as non-commercial clinical research or as out-of-pocket therapy at a physician's discretion, subject to a risk classification and review by a Certified Committee for Regenerative Medicine.
The scale that framework has reached is striking. Since the Act came into force, more than 1,000 regenerative medicine provision plans have been approved, and more than 10,000 patients receive treatment under it each year. There is no comparable lawful market anywhere else.
The Act was amended by Act No. 51 of 14 June 2024, with the amended cabinet order promulgated on 6 December 2024 and the amended ministerial ordinance on 28 February 2025, both taking effect on 31 May 2025. The amendment brings in vivo gene therapy and related technologies into scope as the highest-risk class, requires conflict-of-interest management, requires Certified Committees to conduct a specific assessment of the scientific validity of each provision plan, and creates on-site inspection powers and grounds for disqualifying a committee.
Critically, the new obligations are about the integrity of the review, not about the strength of the claim. A provision plan must now survive a scientific-validity assessment by a committee that can be inspected and disqualified. It still does not have to demonstrate efficacy in the sense a marketing authorisation would require. Safety and process integrity are regulated. Outcome is not.
Korea has now built its own door. The Act on the Safety of and Support for Advanced Regenerative Medicine and Advanced Biological Products took effect in 2020 with a narrow design: advanced regenerative medicine could be administered only inside approved clinical research protocols, and patients could not be charged. As of November 2025, only 50 clinical research plans had been approved under it. The amendment of 20 February 2024, in force from 21 February 2025, creates a new legal category of advanced regenerative medicine treatment that sits outside the clinical research system. Institutions can provide therapies as treatment rather than as research, subject to ethics committee approval and safety standards; treatment plans must state purpose, target population, safety and efficacy evidence and cost calculations.
Singapore has not yet decided its position. Phase 2 licensing under the Healthcare Services Act, expected across 2026 and 2027, will determine whether longevity clinics are classified as medical services or as wellness services. That single classification decision carries more consequence for the regional market than any therapeutic result likely to be published in the same window. Meanwhile, the market is being priced without waiting: a single hyperbaric oxygen session at a private Singapore wellness clinic ran between SGD 250 and SGD 400 as of mid-2026, red light therapy packages started around SGD 120 a session, and cryotherapy in upscale Bangkok centres ran roughly THB 2,500 to THB 4,000.
For a pharmaceutical audience, the significance of route one is that it is establishing the reference price, the patient expectation and the belief system for an entire category, years before a single approved gerotherapeutic reaches the region. Whoever eventually arrives with a registered product will be selling into a market that has already been taught what longevity medicine costs and what it feels like to buy.
Route Two: Borrowing an Adjacent Indication
If aging cannot be filed, something adjacent to it can. The available lanes include sarcopenia (搜索) and muscle health, frailty and intrinsic capacity, fibrotic disease, chronic kidney disease, immunosenescence, and several ophthalmic conditions in which age is the dominant risk factor.
Asia-Pacific's position in this route is genuinely distinctive and almost entirely unmonetised. The Asian Working Group for Sarcopenia (搜索) has done something no other regional body in aging medicine has managed. Its 2014 consensus, revised in 2019, established diagnostic criteria and cut-off values calibrated to Asian body composition rather than imported from European cohorts. The 2025 consensus update, published in Nature Aging in November 2025, goes considerably further: it reframes sarcopenia from a disease diagnosis into a life-course muscle health framework, extends diagnosis to middle-aged adults between 50 and 64 with validated thresholds, simplifies the diagnostic algorithm to concurrent low muscle mass and low strength with physical performance repositioned as an outcome measure, and hooks case-finding into the World Health Organization's Integrated Care for Older People pathway.
Behind it sits pooled cohort work including multinational normative muscle health metrics drawn from eight cohorts across Japan, Malaysia and Taiwan. This is the most consequential contribution Asia-Pacific has made to aging medicine, and it is a diagnostic framework rather than a drug. In a category with no approvable indication, the endpoint is the asset.
Yet the Global Leadership Initiative in Sarcopenia (搜索), working since 2021 towards an international definition, has a steering committee of 22 members, of whom only four are from Asia. The region that produced the criteria most widely used across Asian populations holds under a fifth of the seats where the global replacement is being drafted. Commentary from within the Korean geriatrics community has been notably direct about this, framing it as a failure of regional scientific assertiveness rather than as exclusion.
The pipeline picture reinforces the asymmetry. Senolytic small molecules accounted for the largest share of longevity market revenue in 2025, and the visible programmes are overwhelmingly North American. Unity Biotechnology reported encouraging Phase 2b results for UBX1325 in diabetic macular edema (搜索) in March 2025 and subsequently wound down after clinical failure, having raised around USD 200 million through Series C. Cambrian Bio (搜索) secured a USD 23 million platform extension in January 2026. Asia-Pacific's most visible presence runs through Insilico Medicine (搜索), whose lead clinical asset emerged from aging-biology target selection and is being developed against fibrosis.
What is largely missing is the middle. Between the epidemiology, which is excellent, and the institutes, which are new — including China's Sirio Institute for Anti-Aging launched in February 2025 — there is very little Asia-Pacific-originated therapeutic development running against a borrowed aging-adjacent indication with a disclosed regulatory strategy.
Route Three: Qualifying the Biomarker
The third route attacks the constraint directly. If a biomarker of biological aging could be formally qualified as a surrogate endpoint, the economics of the entire field change: dose-finding studies become feasible, candidate gerotherapeutics can be screened in months instead of decades, and sponsors escape the multi-year, multi-disease composite designs that made trials like TAME so difficult to finance.
The candidate biomarkers are familiar: DNA-methylation clocks including Horvath, GrimAge, PhenoAge and DunedinPACE; plasma proteomic signatures; transcriptomic clocks; inflammatory and immune-aging panels. None of them is a qualified surrogate endpoint in any jurisdiction.
There is a reasonable argument that an Asia-Pacific authority should move first, and it is not being made loudly enough. The region has the population structures that make the question urgent, national biobank and cohort infrastructure in Japan, Korea, Singapore and Taiwan, and health systems with an explicit policy commitment to compressing morbidity rather than extending lifespan. No Asia-Pacific sponsor or authority has filed a qualification package.
What is happening instead is partnership. Life Biosciences (搜索), whose partial epigenetic reprogramming platform received FDA clearance for its ER-100 programme in January 2026 and which dosed its first patient later that year in a Phase 1 trial covering glaucoma and non-arteritic anterior ischemic optic neuropathy, is working with SingHealth's clinical network on translational research. The pattern repeats: platform and regulatory strategy originate in the United States, validation cohorts and clinical networks come from Asia.
Global anti-aging biotech funding reached USD 3.74 billion in the first quarter of 2026, up 56 per cent year on year. Yet biological-age diagnostics remain conspicuously underfunded relative to their prominence in the narrative, with investors appearing to treat biomarkers as enabling infrastructure rather than as the point of value capture.
The Payer Problem
None of the three routes has a payer behind it. Route one is designed to be cash-pay. Routes two and three face a harder version of the same problem: if an agent delays the onset of five age-related conditions by three years each, the saving appears across five separate budget lines over a horizon longer than any electoral cycle, while the cost lands immediately in the pharmaceutical line. No Asia-Pacific payer currently operates a health technology assessment method that can capture value distributed that way.
One underexplored financing route exists: private health insurers and large employers in Japan, Korea, Singapore and Hong Kong carry concentrated exposure to exactly the morbidity that a gerotherapeutic would defer, and they operate on horizons closer to a decade than to a budget cycle. Nothing in the current landscape suggests that conversation has moved beyond wellness benefits and screening packages.
What Would Change the Picture
Three observable developments would move this from a services market to a therapeutics market. The first is a published regulatory position from an Asia-Pacific authority on aging-adjacent endpoints, even in draft — with Singapore's Healthcare Services Act Phase 2 classification as the nearest decision point. The second is an Asia-Pacific sponsor or academic consortium filing a biomarker qualification package rather than contributing cohorts to somebody else's. The third is the Asian Working Group for Sarcopenia (搜索) framework carrying into the global definition with representation proportionate to the populations it was built from.
Until at least one of those happens, the pattern holds. Asia-Pacific will continue to lead the world in delivering longevity interventions and to follow it in proving them, and the price of a longevity intervention across the region will keep being set in clinics rather than in trials.